Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study — Watcharee Rungapiromnan (2019) | RDL Network
Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study
Article 2019 en
Authors
WR
Watcharee Rungapiromnan
KM
K.J. Mason
ML
Mark Lunt
Abstract
1 min read
In this large prospective cohort study, we found no significant differences in the risk of major CVEs between three different biologic therapies and methotrexate. Additional studies, with longer term follow-up, are needed to investigate the potential effects of biologic therapies on incidence of major CVEs.
Ireny Iskandar, Richard B. Warren, Zenas Z N Yiu, Jnwn Barker, David Burden, A.D. Ormerod, Nick J. Reynolds, Catherine Smith, Christopher Em Griffiths, Darren M. Ashcroft
Avni Jain, Ruth Ann Marrie, Leigh Anne Shafer, Lesley A. Graff, Scott Burton Patten, Renée El‐Gabalawy, Jitender Sareen, James M. Bolton, John D. Fisk, Çharles N. Bernstein
David Kaplan, M. Elaine Husni, Eunice Chang, Michael S. Broder, Caleb Paydar, Katalin Bognar, Jessie T. Yan, Sven Richter, Pooja Desai, Ibrahim Khilfeh
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.